Trial Profile
A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Glycopyrrolate; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms SPARK
- Sponsors Novartis Pharmaceuticals
- 24 Jul 2019 Results of pooled post hoc analysis of data from the ARISE (NCT01285492), SHINE (NCT01202188) and SPARK (NCT01120691) studies evaluating the efficacy of Indacaterol/glycopyrronium versus open label Tiotropium or glycopyrronium in COPD patients published in the Respirology
- 18 May 2016 Results of a post-hoc analysis presented at the 112th International Conference of the American Thoracic Society
- 16 May 2014 Results on patient reported symptom scores presented at the 110th International Conference of the American Thoracic Society.